Table 1: Baseline and follow-up measures for men with prostate cancer participating in a presurgical weight loss trial (n = 32).
Baseline Mean ± SD | Follow-up Mean ± SD | Change Mean ± SD | |
Body weight (kg) | 96.4 ± 13.8 | 93.0 ± 13.3 | -3.4 ± 3.9*** |
Body Mass Index (kg/m2) | 31.1 ± 4.4 | 30.0 ± 4.2 | -1.1 ± 1.3*** |
Percent body fata | 36.0 ± 5.5 | 34.6 ± 5.5 | -1.4 ± 1.9*** |
Caloric Intakeb | 1587 ± 525 | 1298 ± 432 | 289 ± 667* |
Stage 1 VO2 | 10.1 ± 1.9 | 9.6 ± 2.0 | -0.4 ± 1.7 |
Stage 2 VO2 | 13.1 ± 2.1 | 12.5 ± 2.2 | -0.5 ± 2.2 |
Stage 1 HR | 96.1 ± 13.3 | 90.1 ± 13.3 | -6.0 ± 9.9** |
Stage 2 HR | 106.8 ± 14.2 | 100.1 ± 13.3 | -6.7 ± 10.6** |
Stage 1% of max HR | 0.601 ± 0.086 | 0.563 ± 0.087 | -0.038 ± 0.062** |
Stage 2% of max HR | 0.667 ± 0.088 | 0.626 ± 0.086 | -0.041 ± 0.066** |
Predicted VO2max | 25.0 ± 2.0 | 25.8 ± 2.1 | 0.8 ± 1.5** |
Predicted Lean mass VO2maxa | 42.0 ± 1.4 | 41.7 ± 1.4 | -0.3 ± 1.1 |
an = 31 due to no DEXA data; bAverage of two-24 hour dietary recalls, n = 28; Stage 1: 3.22 km/hr, no incline; Stage 2: 3.22 km/hr, 4% incline; *p < 0.01; **p < 0.05; ***p < 0.001, significant at p < 0.004.